Physician profile
John Denoon Evans
NPI 1386646644
$516.18
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.45 · 2021: $146 · 2022: $66.23 · 2023: $49.96 · 2024: $36.73 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $89.68 | 2021-2023 | Cequa |
| Regeneron Healthcare Solutions, INC. | $72.30 | 2021-2025 | Eylea Hd |
| Alcon Vision LLC | $61.19 | 2021-2025 | Hydrus Microstent |
| Amgen INC. | $49.77 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $48.65 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $41.83 | 2025 | Izervay |
| Horizon Therapeutics Plc | $33.59 | 2021-2023 | Tepezza |
| Shire North American Group INC | $33.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.56 | 2021 | |
| Omeros Corporation | $22.45 | 2019 | |
| Genentech USA, INC. | $20.65 | 2022 | |
| Rayner Intraocular Lenses Limited | $13.51 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.